Compare · DFTX vs RLX
DFTX vs RLX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.10B, about 1.2x DFTX ($2.57B).
- Over the past year, DFTX is up 186.4% and RLX is down 10.0% - DFTX leads by 196.4 points.
- DFTX has been more active in the news (3 items in the past 4 weeks vs 2 for RLX).
- DFTX has more recent analyst coverage (4 ratings vs 2 for RLX).
PerformanceDFTX+186.41%RLX-9.95%
2025-06-09+0.00%2026-06-08
- Company
- Definium Therapeutics Inc.
- RLX Technology Inc.
- Price
- $22.24-5.60%
- $1.99-0.25%
- Market cap
- $2.57B
- $3.10B
- 1M return
- -4.30%
- -7.44%
- 1Y return
- +186.41%
- -9.95%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 2
- Recent ratings
- 4
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao